News
-
-
PRESS RELEASE
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Immunic receives United States Patent Notice of Allowance for Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis, extending protection into 2041 -
-
-
-
-
-
PRESS RELEASE
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic reports positive long-term data from phase 2 EMPhASIS Trial of Vidofludimus Calcium in relapsing-remitting multiple sclerosis, showing favorable safety & tolerability profile up to 5.5 years -
-
PRESS RELEASE
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic completes enrollment for Phase 3 ENSURE trials in Relapsing MS and presents positive Phase 2 CALLIPER trial data in Progressive MS, showcasing vidofludimus calcium's potential. Top-line data in 2026
